Research Esophageal Cancer Pediatrics Bioengineering
It looks pretty simple: A capsule the size of a jelly bean, attached to a string. And yet, it shows promise as an answer to a vexing question in the fight against esophageal cancer and other diseases of the upper digestive tract: How to spare patients from repeated endoscopies and biopsies.
Clinical Research Obesity Pediatrics
A pilot grant funded in part by the University of Colorado Cancer Center will support a study that will look at factors contributing to extreme obesity in children with a type of benign brain tumor.
The fear, anger, and anxiety that come with a cancer diagnosis are only magnified in children, who—along with their family members—often need help working through the emotions that surround cancer diagnosis, treatment, and survivorship.
Pediatric Cancer Brain and Spinal Cancer Pediatrics
May is Brain Tumor Awareness Month, which makes it a perfect time to turn the spotlight on pediatric brain cancer. Brain cancer is the second most common cancer in children, after leukemia, and brain tumors are the most common solid tumors in children and adolescents, with more than 4,000 new diagnoses each year, according to the American Cancer Society.
Pediatric Cancer Brain and Spinal Cancer Cancer Pediatrics
Researchers at the University of Colorado Anschutz Medical Campus have discovered a drug combination that might offer a better prognosis for children diagnosed with MYC amplified Medulloblastoma, an often deadly form of brain cancer. The research was conducted in collaboration with the German Cancer Consortium (DKTK) University Hospital Dusseldorf.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Mark Harden
